Aceite de silicona pesado (Densiron ® 68) en vitreorretinopatía proliferativa: 4 años de experiencia

  1. Macías-Murelaga, B.
  2. Ruiz-Miguel, Miguel
  3. Bascarán, L.
  4. Gibelalde González, Ana
  5. Aldazabal, M.
  6. Irigoyen, C.
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2013

Volume: 88

Issue: 11

Pages: 445-449

Type: Article


More publications in: Archivos de la Sociedad Española de Oftalmologia


Method Prospective observational study including 10 patients (age range: 27-74 years) with recurrent retinal detachment (RD) and proliferative vitreoretinopathy (PVR) and 2.8 mean unsatisfactory previous surgeries. Densiron® was injected in all patients, with surgical retinectomy being required in 70% of them. Minimum follow-up time was 12 months. Results The mean length of time before Densiron® withdrawal was 4 months. Three patients (30%) presented with a new RD. The main complication detected was cataract development. No relationship was found between re-detachments and tamponade time, baseline disease or RD evolution time. Densiron® may be a good option in cases of recurrent RD in which previous treatment with scleral buckle, gas and/or 1,000/5,000 silicone oils has proven to be unsatisfactory.